Learn more about our policy experts.

Media Contacts

Angela Bradbery, Director of Communications
w. (202) 588-7741
c. (202) 503-6768
abradbery@citizen.org, Twitter

Don Owens, Deputy Director of Communications
w. (202) 588-7767

David Rosen, Press Officer, Regulatory Affairs
w. (202) 588-7742

Luis Castilla, Press Officer, Public Citizen’s Texas office
w. (512) 637-9467

Other Important Links

Press Release Database
Citizen Vox blog
Texas Vox blog
Consumer Law and Policy blog
Energy Vox blog
Eyes on Trade blog

Follow us on Twitter


July 15, 2010

Weight Loss Drug Too Dangerous to Be Allowed On Market

Public Citizen's Dr. Sidney Wolfe Testifies Before FDA Advisory Committee

Dr. Sidney Wolfe, director of Public Citizen's Health Research Group, testified today before an FDA advisory committee about a proposed new weight-loss drug, Qnexa. In his testimony, prepared by himself and Dr. Charles Preston of the Johns Hopkins Bloomberg School of Public Health, he said the drug is too dangerous too approve. Qnexa is a combination of two old drugs, phentermine and topiramate, each of which has significant risks. One is an amphetamine; the other, an anti-seizure medication.

Phentermine affects many different organ systems, including the neurologic, cardiovascular, and gastrointestinal. It increases heart rate and blood pressure, heightens wakefulness, and decreases appetite.

Studies of topiramate show that cognition is impaired in people who take the drug, particularly regarding attention, memory, and language. The same is seen with Qnexa. It was hypothesized that by adding an amphetamine, the negative cognitive effects of topiramate might be mitigated. But we see just the opposite-that the combination is worse than the topiramate alone. Further, anti-epileptic drugs - especially topiramate - have long been known to increase the risk of suicidal ideation relative to placebo.

Qnexa carries a long list of serious side effects. In fact, adverse events were the major reason patients failed to complete the trials of the drug; 18% of high-dose subjects withdrew due to an adverse event, compared to 9% for a placebo.

Perhaps one of the most important prior studies relevant to today’s decision was a randomized, placebo controlled trial of topiramate controlled release (CR) for overweight and obese patients with type 2 diabetes. The treatment group underwent 16 weeks of therapy, up to a dose of 175 mg/day. The investigators found that the cognitive and psychiatric effects were similar to those seen with Qnexa-- namely higher rates of anxiety, memory difficulties, and insomnia compared to placebo-- and they concluded that the “CNS and psychiatric adverse event profile of topiramate CR makes it unsuitable for the treatment of obesity and diabetes.”  "We couldn’t agree more strongly," Dr. Wolfe said.

To read the testimony, visit http://www.citizen.org/hrg1914.


Copyright © 2017 Public Citizen. Some rights reserved. Non-commercial use of text and images in which Public Citizen holds the copyright is permitted, with attribution, under the terms and conditions of a Creative Commons License. This Web site is shared by Public Citizen Inc. and Public Citizen Foundation. Learn More about the distinction between these two components of Public Citizen.

Public Citizen, Inc. and Public Citizen Foundation


You can support the fight for greater government and corporate accountability through a donation to either Public Citizen, Inc., or Public Citizen Foundation, Inc.

Public Citizen lobbies Congress and federal agencies to advance Public Citizen’s mission of advancing government and corporate accountability. When you make a contribution to Public Citizen, you become a member of Public Citizen, showing your support and entitling you to benefits such as Public Citizen News. Contributions to Public Citizen are not tax-deductible.

Public Citizen Foundation focuses on research, public education, and litigation in support of our mission. By law, the Foundation can engage in only very limited lobbying. Contributions to Public Citizen Foundation are tax-deductible.